JPMorgan Chase & Co. lowered shares of Endo International (NASDAQ:ENDP) (TSE:ENL) from a neutral rating to an underweight rating in a research report released on Monday morning, 24/7 WallStreet reports. They currently have $9.00 target price on the stock.

Other equities research analysts have also recently issued research reports about the stock. BidaskClub cut shares of Endo International from a buy rating to a hold rating in a research report on Wednesday, March 27th. ValuEngine cut shares of Endo International from a hold rating to a sell rating in a research report on Wednesday, May 1st. Gabelli reissued a hold rating on shares of Endo International in a research report on Wednesday, March 27th. Canaccord Genuity set a $17.00 target price on shares of Endo International and gave the company a buy rating in a research report on Friday, March 8th. Finally, Zacks Investment Research raised shares of Endo International from a sell rating to a hold rating in a research report on Tuesday, February 26th. Two equities research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating and six have given a buy rating to the stock. Endo International currently has a consensus rating of Hold and an average price target of $14.88.

Shares of Endo International stock opened at $6.61 on Monday. The stock has a market capitalization of $1.46 billion, a PE ratio of 2.29 and a beta of 1.12. Endo International has a 52-week low of $5.92 and a 52-week high of $18.50.

Endo International (NASDAQ:ENDP) (TSE:ENL) last announced its earnings results on Thursday, May 9th. The company reported $0.53 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.42 by $0.11. The company had revenue of $720.00 million during the quarter, compared to analysts’ expectations of $692.31 million. Endo International had a negative net margin of 18.35% and a negative return on equity of 199.18%. Endo International’s quarterly revenue was up 2.9% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.67 earnings per share. On average, sell-side analysts forecast that Endo International will post 2.2 EPS for the current year.

Hedge funds have recently bought and sold shares of the stock. LS Investment Advisors LLC acquired a new position in Endo International during the fourth quarter worth about $59,000. Oregon Public Employees Retirement Fund acquired a new position in Endo International during the fourth quarter worth about $76,000. First Quadrant L P CA acquired a new position in Endo International during the fourth quarter worth about $92,000. Signition LP acquired a new position in Endo International during the first quarter worth about $139,000. Finally, Neuburgh Advisers LLC raised its stake in Endo International by 13.9% during the fourth quarter. Neuburgh Advisers LLC now owns 24,860 shares of the company’s stock worth $181,000 after acquiring an additional 3,036 shares in the last quarter. 94.93% of the stock is owned by institutional investors and hedge funds.

Endo International Company Profile

Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally. The company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals, and International Pharmaceuticals.

See Also: What is Compound Interest?

Analyst Recommendations for Endo International (NASDAQ:ENDP)

Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.